TME PHARM.CONF.IPO EO 1- Total Assets
TME PHARM.CONF.IPO EO 1- total assets. Based on the latest financial reports, TME PHARM.CONF.IPO EO 1- (0N6A) holds total assets worth €2.14 Million EUR (≈ $2.50 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TME PHARM.CONF.IPO EO 1- stock valuation for the company's overall valuation and market capitalisation.
Total Assets of TME PHARM.CONF.IPO EO 1- (2021–2025)
Total assets of TME PHARM.CONF.IPO EO 1- from 2021 to 2025. This chart illustrates how TME PHARM.CONF.IPO EO 1-'s total assets have evolved over time, based on quarterly financial data. See 0N6A share price today for real-time trading data and today's change.
TME PHARM.CONF.IPO EO 1- - Asset Composition Analysis
TME PHARM.CONF.IPO EO 1- Total Assets Breakdown (December 2025)
TME PHARM.CONF.IPO EO 1- total assets breakdown as of December 2025. TME PHARM.CONF.IPO EO 1-'s total assets of €2.14 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 94.1% |
| Accounts Receivable | €2.00K | 0.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.00K | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how TME PHARM.CONF.IPO EO 1-'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TME PHARM.CONF.IPO EO 1- working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TME PHARM.CONF.IPO EO 1-'s current assets represent 99.2% of total assets in 2025, a decrease from 99.2% in 2021.
- Cash Position: Cash and equivalents constituted 94.1% of total assets in 2025, down from 96.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 0.2% of total assets.
TME PHARM.CONF.IPO EO 1- Competitors by Total Assets
Key competitors of TME PHARM.CONF.IPO EO 1- based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
TME PHARM.CONF.IPO EO 1- - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.57 | 1.88 | 2.11 |
| Quick Ratio | 0.57 | 1.88 | 2.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-1.60 Million | €1.57 Million | €1.52 Million |
TME PHARM.CONF.IPO EO 1- - Advanced Valuation Insights
This section examines the relationship between TME PHARM.CONF.IPO EO 1-'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.94 |
| Latest Market Cap to Assets Ratio | 4.88 |
| Asset Growth Rate (YoY) | -37.2% |
| Total Assets | €2.14 Million |
| Market Capitalization | $10.44 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values TME PHARM.CONF.IPO EO 1-'s assets at a significant premium (4.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: TME PHARM.CONF.IPO EO 1-'s assets decreased by 37.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TME PHARM.CONF.IPO EO 1- (2021–2025)
The table below shows the annual total assets of TME PHARM.CONF.IPO EO 1- from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.14 Million ≈ $2.50 Million |
-37.20% |
| 2024-12-31 | €3.41 Million ≈ $3.98 Million |
+36.73% |
| 2023-12-31 | €2.49 Million ≈ $2.91 Million |
-52.47% |
| 2022-12-31 | €5.24 Million ≈ $6.13 Million |
-46.35% |
| 2021-12-31 | €9.77 Million ≈ $11.42 Million |
-- |
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indicatio… Read more